Literature DB >> 8930201

Search for lead structures to develop new allosteric modulators of muscarinic receptors.

C Tränkle1, E Kostenis, U Burgmer, K Mohr.   

Abstract

Various compounds are known to allosterically modulate the binding of ligands to muscarinic receptors. Most of these compounds have another predominant pharmacological action. Identification of the potent representatives should be useful for the development of allosteric modulators that are specific and highly active. For various reasons, a direct comparison of allosteric potencies on the basis of literature data is difficult. Therefore, a series of compounds was compared with regard to the allosteric delay of the dissociation of N-[3H]methylscopolamine from porcine heart M2 receptors under the following assay conditions: "Na,K,Pi buffer", 4 mM Na2HPO4, 1 mM KH2PO4, pH 7.4, 23 degrees C; "Mg,Tris,Cl,Pi buffer', 50 mM Tris-HCl, 3 mM MgHPO4,pH 7.3, 37 degrees C. Generally, the allosteric potency of the compounds was higher in the Na,K,Pi buffer, compared with the Mg,Tris,Cl,Pi buffer. However, the extent of the potency shift differed, ranging from approximately 2-fold for tacrine to approximately 100-fold for gallamine. The concentration retarding radioligand dissociation to half of the control rate (EC50) served as a measure of allosteric potency. Under both assay conditions, alcuronium was the most potent compound (EC50,Na,K,Pi = 4 nM and EC50,Mg,Tris,Cl,Pi = 55 nM), followed by alkane-bisammonium and bispyridinium compounds containing phthalimido moieties. Gallamine showed intermediate potency (EC50 values of 180 nM and 16,000 nM in Na,K,Pi buffer and Mg,Tris,Cl,Pi buffer, respectively). Obidoxime and hexamethonium, both known to antagonize allosteric actions, revealed submaximal efficacy and low potency (EC50,Na,K,Pi of approximately 100,000 nM). The relevance of these results, regarding the identification of lead structures for the development of new allosteric modulators, is discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8930201

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

1.  DFT calculation of four new potential agents muscarinic of bispyridinium type: structure, synthesis, biological activity, hydration, and relations with the potents W84 and DUO-3O.

Authors:  M Alcolea Palafox; P Posada-Moreno; A L Villarino-Marín; C Martinez-Rincon; I Ortuño-Soriano; I Zaragoza-García
Journal:  J Comput Aided Mol Des       Date:  2010-12-22       Impact factor: 3.686

2.  Allosteric site in M2 acetylcholine receptors: evidence for a major conformational change upon binding of an orthosteric agonist instead of an antagonist.

Authors:  Maren Grossmüller; Johannes Antony; Christian Tränkle; Ulrike Holzgrabe; Klaus Mohr
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-12-16       Impact factor: 3.000

3.  Subtype-selective inhibition of [methyl-3H]-N-methylscopolamine binding to muscarinic receptors by alpha-truxillic acid esters.

Authors:  M Lysíková; K Fuksová; T Elbert; J Jakubík; S Tucek
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

Review 4.  Rational design of dualsteric GPCR ligands: quests and promise.

Authors:  Klaus Mohr; Christian Tränkle; Evi Kostenis; Elisabetta Barocelli; Marco De Amici; Ulrike Holzgrabe
Journal:  Br J Pharmacol       Date:  2010-02-05       Impact factor: 8.739

5.  Novel allosteric effects of amiodarone at the muscarinic M5 receptor.

Authors:  Edward Stahl; John Ellis
Journal:  J Pharmacol Exp Ther       Date:  2010-03-26       Impact factor: 4.030

6.  Cooperative interactions at M2 muscarinic acetylcholine receptors: structure/activity relationships in stepwise shortened bispyridinium- and bis(ammonio)alkane-type allosteric modulators.

Authors:  Ralf Gilsbach; Maren Grossmüller; Vildan Alptüzün; Ercin Erciyas; Christian Tränkle; Ulrike Holzgrabe; Klaus Mohr
Journal:  Neurochem Res       Date:  2003-04       Impact factor: 3.996

7.  Agonists with supraphysiological efficacy at the muscarinic M2 ACh receptor.

Authors:  R Schrage; W K Seemann; J Klöckner; C Dallanoce; K Racké; E Kostenis; M De Amici; U Holzgrabe; K Mohr
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

8.  Autoantibodies enhance agonist action and binding to cardiac muscarinic receptors in chronic Chagas' disease.

Authors:  Ciria C Hernandez; Jose H Nascimento; Elen A Chaves; Patricia C Costa; Masako O Masuda; Eleonora Kurtenbach; Antonio C Campos DE Carvalho; Luis E Gimenez
Journal:  J Recept Signal Transduct Res       Date:  2008       Impact factor: 2.092

9.  Characterization of methanthelinium binding and function at human M1-M5 muscarinic acetylcholine receptors.

Authors:  Matthias Irmen; Janine Holze; Theresa Bödefeld; Christian Tränkle
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-06-24       Impact factor: 3.000

10.  Semisynthetic analogues of toxiferine I and their pharmacological properties at α7 nAChRs, muscle-type nAChRs, and the allosteric binding site of muscarinic M2 receptors.

Authors:  Darius P Zlotos; Christian Tränkle; Ulrike Holzgrabe; Daniela Gündisch; Anders A Jensen
Journal:  J Nat Prod       Date:  2014-09-05       Impact factor: 4.050

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.